Iran Conflict Pushes Pharma Raw Material Prices Up: Are Medicines Set to Get Costlier?

Iran Conflict Drives Up Pharma Raw Material Costs: Vitamins and Antibiotics Under Pressure

The ongoing conflict between Iran and the US-Israel coalition in West Asia is affecting India’s pharmaceutical supply chain, pushing up costs of key raw materials and raising concerns over medicine prices. Industry executives report sharp rises in key starting materials (KSMs) and active pharmaceutical ingredients (APIs), with some inputs increasing 5–100% in just the past week due to currency fluctuations, rising oil-linked solvent costs, and global shipping disruptions.

Major Price Hikes

Muscle relaxant Thiocolchicide saw one of the steepest increases, surging from Rs 3.4 lakh to Rs 7 lakh—a jump of over 100%. Other inputs, including glycerin, nimesulide, deflazacort, and clobetasol propionate, have risen 45–65%. Several antibiotics and common drugs such as ciprofloxacin, cefpodoxime, amikacin, paracetamol, and diclofenac have also become costlier by 20–30%.

Despite the rise, many medicine prices in India remain regulated by the National Pharmaceutical Pricing Authority (NPPA), forcing companies to absorb higher production costs.

Reasons Behind the Surge

Industry experts point to multiple factors: the US dollar’s strength against the rupee, rising oil prices affecting essential solvents like methanol and acetone, and logistical disruptions. “Solvent costs are closely linked to petroleum. With oil prices up, the cost of solvents has risen 20–25% in the past few days,” said Udaya Bhaskar, former director-general of the Pharmaceuticals Export Promotion Council of India. Shipping delays and container shortages have compounded the problem.

Impact on Manufacturers

Smaller drugmakers and MSMEs are expected to feel the brunt, especially for high-volume, low-value drugs such as paracetamol and omeprazole. Vitamins and nutritional ingredients, heavily imported from China, are already seeing price increases, as are antibiotics—particularly the cephalosporin class.

With the situation in West Asia still volatile, manufacturers are closely monitoring oil prices, currency fluctuations, and shipping routes, all of which could further drive up costs of pharmaceutical raw materials and, eventually, medicine prices in India.